ScholarIQanswers from OpenAlex & ORCID
Ian E. Krop
ResearcherPublications, citations & collaboration network
Ian E. Krop is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Ian E. Krop have?
ScholarIQindexed works
Ian E. Krop has 881 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Ian E. Krop have?
ScholarIQcitation count
Ian E. Krop has 43,251 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Ian E. Krop?
ScholarIQh-index
Ian E. Krop has an h-index of 101 in OpenAlex.
What is the i10-index of Ian E. Krop?
ScholarIQi10-index
Ian E. Krop has an i10-index of 268 in OpenAlex.
What is the ORCID of Ian E. Krop?
ScholarIQorcid
The ORCID for Ian E. Krop is on the source record.
What is the OpenAlex record for Ian E. Krop?
ScholarIQopenalex
The OpenAlex for Ian E. Krop is on the source record.
What are the most-cited papers on Ian E. Krop?
ScholarIQmost cited works
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Fátima Cardoso, A. Costa, Elżbieta Senkus, Matti Aapro, Fabrice André, Carlos H. Barrios, Jonas Bergh, G.S. Bhattacharyya, Laura Biganzoli, Maria João Cardoso, L. Carey, D. Corneliussen-James, Giuseppe Curigliano, Véronique Dièras, N. El Saghir, Alexandru Eniu, Lesley Fallowfield, D. Fenech, Prudence A. Francis, Karen A. Gelmon, Alessandra Gennari, Nadia Harbeck, Clifford A. Hudis, Bella Kaufman, Ian E. Krop, Musa Mayer, Hanneke Meijer, Shirley Mertz, Shinji Ohno, Olivia Pagani, Efthymios Papadopoulos, Fedro A. Peccatori, Frédérique Penault‐Llorca, Martine Piccart, Jean‐Yves Pierga, Hope S. Rugo, Lillie D. Shockney, George W. Sledge, Sandra M. Swain, Christoph Thomssen, Andrew Tutt, Daniel Vorobiof, Binghe Xu, Larry Norton, Eric P. Winer
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Rashmi K. Murthy, Sherene Loi, Alicia Okines, Elisavet Paplomata, Erika Hamilton, Sara A. Hurvitz, Nancy U. Lin, Virginia F. Borges, Vandana G. Abramson, Carey K. Anders, Philippe L. Bédard, Mafalda Oliveira, Erik Jakobsen, Thomas Bachelot, Shlomit Strulov Shachar, Volkmar Müller, Sofía Braga, François P. Duhoux, Richard Greil, David Cameron, Lisa A. Carey, Giuseppe Curigliano, Karen A. Gelmon, Gabriel N. Hortobágyi, Ian E. Krop, Sibylle Loibl, Mark D. Pegram, Dennis J. Slamon, Maria Corinna Palanca-Wessels, Luke Walker, Wentao Feng, Eric P. Winer
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
Sara M. Tolaney, William T. Barry, Chau T. Dang, Denise A. Yardley, Beverly Moy, P. Kelly Marcom, Kathy S. Albain, Hope S. Rugo, Matthew J. Ellis, Iuliana Shapira, Antonio C. Wolff, Lisa A. Carey, Beth Overmoyer, Ann H. Partridge, Hao Guo, Clifford A. Hudis, Ian E. Krop, Harold J. Burstein, Eric P. Winer
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
Shaokun Shu, Charles Y. Lin, Housheng Hansen He, Robert M. Witwicki, Doris P. Tabassum, Justin M. Roberts, Michalina Janiszewska, Sung Jin Huh, Yi Liang, Jeremy Ryan, Ernest Doherty, Hisham Mohammed, Hao Guo, Daniel G. Stover, Muhammad B. Ekram, Guillermo Peluffo, Jonathan D. Brown, Clive S. D’Santos, Ian E. Krop, Deborah Dillon, Michael R. McKeown, Christopher J. Ott, Jun Qi, Min Ni, Prakash K. Rao, Melissa Duarte, Shwu-Yuan Wu, Cheng-Ming Chiang, Lars Anders, Richard A. Young, Eric P. Winer, Antony Letai, William T. Barry, Jason S. Carroll, Henry W. Long, Myles Brown, X. Shirley Liu, Clifford A. Meyer, James E. Bradner, Kornélia Polyák
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
Lisa A. Carey, Donald A. Berry, Constance Cirrincione, William T. Barry, Brandelyn N. Pitcher, Lyndsay N. Harris, David W. Ollila, Ian E. Krop, N. Lynn Henry, Douglas Weckstein, Carey K. Anders, Baljit Singh, Katherine A. Hoadley, Michael D. Iglesia, Maggie C.U. Cheang, Charles M. Perou, Eric P. Winer, Clifford A. Hudis